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Introduction  and  objectives:  Several existing models have been developed to predict positive prostate
biopsy among men undergoing evaluation for prostate cancer (PCa). However, most of these models have
come from industrialized countries. We therefore, developed a prostate disease nomogram model to provide
a basis for predicting a prostate biopsy outcome by correlating clinical indicators and diagnostic parameters
among Ghanaian men.
Subjects  and  methods:  The study was a hospital-based cross-sectional prospective one which was under-
taken at the Department of Surgery (Urology Unit) Komfo Anokye Teaching Hospital (KATH) from16. In all a total of 241 patients suspected of having a prostate disorder due
ectal examination (DRE) findings and, or elevated prostate specific antigen
ectal Ultrasonography (TRUS) guided biopsy of the prostate. Stepwise logis-
rmine the independent predictors of a positive initial biopsy. Age, prostate-
 rectal examination (DRE) status, prostate specific antigen density (PSAD),
RE, digital rectal examination; PSAD, prostate specific antigen density;December, 2014 to March, 20
based on an abnormal digital r
(PSA) level underwent Trans-R
tic regression was used to dete
specific antigen (PSA), digital
Abbreviations: PCa, prostate cancer; PSA, prostate specific antigen; D
BPH, benign prostatic hyperplasia; AUC, area under curve; KATH, Komfo Anokye Teaching Hospital; ROC, receiver operating characteristics;
TRUS, trans rectal ultrasonography.
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history of alcohol consumption and history of smoking findings were included in the analysis. Two nomo-
gram models were developed that were based on these independent predictors to estimate the probability
of a positive initial prostate biopsy. Receiver-operating characteristic curves (ROC) were used to assess
the accuracy of using the nomograms and PSA and PSAD levels for predicting positive a prostate biopsy
outcome.
Results:  Prostate cancer was diagnosed in 63 out of 241 patients (26.1%). Benign prostatic hyperplasia
was diagnosed in 172 (71.4%) of patients and the remaining 6 patients (2.48%) had chronic inflammation.
Significantly elevated levels of PSA and PSAD were observed among patients with PCa compared to patients
without PCa (p < 0.05). Furthermore, it was observed that age, DRE, PSA, PSAD, history of smoking, and
history of alcohol consumption were significantly independent predictors (p < 0.05) of prostate cancer. The
area under the receiver operating characteristic curve (AUC) of nomogram I and II were 87.3 and 84.8
respectively which were greater than that of total PSA (AUC = 75.8) and PSAD (AUC = 77.8) alone for
predicting a positive initial prostate biopsy
Conclusion:  We conclude that, nomograms offer a better and accurate assessment for predicting a positive
outcome of prostate biopsies than the use of traditional tools of PSA, DRE and PSAD alone.

































































access article under 
ntroduction
rostate cancer has been the most commonly diagnosed cancer and
he second leading cause of cancer-related death in men in the United
tates in 2011. It is the number one cancer in both incidence and mor-
ality in Africa, constituting of 13% of all male cancer occurrence
nd 11.3% of all male cancer related mortalities [1]. In African coun-
ries where registers exist such as Nigeria, Uganda, South Africa and
imbabwe, it has been observed that the incidence of prostate cancer
s increasing between the ages of 40 to 70 years [1]. Rretrospective
tudies of all cancer cases have demonstrated that prostate cancer
as the second leading cause of cancer-related mortality among
ale patients in Ghana [2–4].
ecently, controversy has arisen as to whether an early detection
f prostate cancer through accurate determination of DRE, prostate
pecific antigen (PSA) screening and its derivatives is actually ben-
ficial or not [5]. This diagnostic gap exposes men to intensive
iagnostic screening and invasive management strategies that affect
uality of life. Prostate biopsies give an absolute diagnosis though it
s expensive and aggressive. Due to the pains and associated prob-
ems, the procedure should be circumvented in men with a low
rostate cancer probability [6,7].
o improve the rates of prostate cancer detection and to reduce
ssociated problems, predictive models for prostate cancer using
aboratory, clinical and ultrasound parameters have been devel-
ped [8–10]. At present, numerous prevailing models had been
eveloped to predict positive prostate biopsy outcome among men
ndertaking assessment for cancer of the prostate [11]. However,
hese models mostly come from industrialized countries. Moreover,
rostate cancer is thought to differ epidemiologically and biolog-
cally between Western, American, African-American and Asian
opulations. Furthermore, nomograms developed for other popu-
ations cannot directly be applied to the Ghanaian population in
ub-Saharan Africa, where there is a higher incidence of prostate
ancer compared to Asian and Western populations [12]. The exist-
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isk should be tailored along racial lines [13–15]. Consequently, the
evelopment and use of a localized nomogram for given popula-
ion is particularly pertinent. To our knowledge, no nomogram to
valuate the risk of prostate cancer in a Ghanaian population setting
as been studied and published to date. It was against this back-
round that this study was carried out to develop a prostate specific
omogram for predicting positive prostate biopsy among Ghanaian
en.
ubjects  and  methods
tudy  design/setting
 hospital-based cross-sectional prospective study was used to
ssess the diagnostic accuracy of PSA, DRE and PSAD among
en undergoing an initial Trans-rectal ultrasound guided (TRUS)
rostate biopsy at Komfo Anokye Teaching Hospital (KATH)
etween December, 2014 and March, 2016. Komfo Anokye Teach-
ng Hospital is a tertiary referral teaching hospital located in
umasi, the regional capital of the Ashanti region in Ghana
ith a total projected population of 4,780,380 according to the
hana Statistical Service, 2010. It is the second largest Hospital
n Ghana.
tudy  population/subject  selection
on-probability convenience sampling technique was used to
ecruit 241 patients visiting the Urology Unit at the directorate
f Surgery, KATH. Indications for TRUS biopsy were an elevated
otal PSA, defined as > 4.0 ng/ml or an a digital rectal examina-
ion, which reveals an abnormal or suspicion of cancer, defined
s the presence of a nodule, areas of induration or asymmetry in
he size lateral lobes. A structured questionnaire was used to elicit
ocio-demographics such as age, educational status, marital status
nd religion. Furthermore, various identified risk factors including
moking, family history of prostate cancer, number of sexual part-
























Nomogram for predicting the probability of the positive outcome 
sexual intercourse, heart attack as well as rheumatoid arthritis were
noted.
Estimation  of  PSA,  DRE,  and  trans  rectal  ultrasound  biopsy
Prior to ultrasonography, five millilitres (5 ml) of blood was col-
lected into a vacutainer(R), and centrifuged to obtain the serum
used for total PSA assay. The assay was performed using the
electrochemiluminiscence method (Cobas e411 Analyzer, Roche
Diagnostics, Germany). Trans-rectal ultrasonography was per-
formed using an endocavitary convex probe with a 6.5 MHz
transducer. Measures of the triaxial distances of the prostate were
taken in its larger diameter and total volume was calculated using
the formula; volume 0.52 ×  transverse diameter ×  anterior poste-
rior diameter ×  longitudinal diameter. The PSAD was calculated as
PSA (ng/ml) divided by the prostate volume (ml) and expressed
as ng/ml/ml. Value of PSAD taken to be indicative of cancer was
>0.15 ng/ml/ml. Digital rectal examination (DRE) was performed
on each subject by an experienced urologist. Trans rectal biopsies of
the prostate were also performed by an experienced urologist with
an 18-gauge automatic Tru-cut biopsy needle (Sonocare, Shang-
hai P.R.C) trans-rectal ultrasonography. All acquired specimens
were placed in a formalin-filled container and sent for histopatho-
logic examination. They were all examined by a board-certified
pathologist at the department of Pathology, Komfo Anokye Teach-
ing Hospital. All the pathologists were blinded from the clinical




Table  1  Comparison of clinical, prostate related characteristics and diag
Variables All participants (n = 241) P
Age (years, mean ± SD) 70.3 ± 8.3 7
Age groups
50–59 23 (9.5%) 2
60–69 82 (34.0%) 1
70–79 36 (14.9% 3
80+ 32 (13.3%) 7
PSA (ng/ml, Median IQR) 18.6 (6.9–28.0) 2
PSA category (ng/ml) 
≤4.0 30 (12.5%) 1
4.1–10 56 (23.2%) 4
10.1–20 39 (16.2%) 7
20.1 50 81 (33.6%) 2
>50 35 (14.5%) 2
DRE findings 
Positive 102 (42.3%) 4
Negative 139 (57.7%) 1
PSAD (ng/ml/ml, Median IQR) 0.17 (0.08–0.41) 0
PSAD category 
<0.15 121 (46.1%) 1
≥0.15 130 (53.9%) 5
Prostate volume (ml, median IQR) 83.1 (60.9–124.5) 8
Prostate volume category 
<40 24 (10.0%0 6
40–80 89 (36.9%) 1
>80 128 (53.1%) 9
Qmax 9.0 (6.0–12.9) (
Vcomp 106.0 (88.2–127.0) 1
I-PSS score 21.6 ± 5.8 2
DRE = digital rectal examination, PSA = prostate specific antigen, PSAD = pros
IPSS = International prostate symptoms score.47
tatistical  analysis
ata entry and analysis were performed using Stata version 12.
escriptive statistics was performed for demographic variables,
xpressed as mean and standard deviation in the case of contin-
ous variables with normal distribution. In case of asymmetrical
istribution, the median and inter quartile (IQR) values were
sed. Comparisons of variables (age, prostate volume, PSA and
SAD) between the patients with and without prostate cancer were
one with t-test and Mann–Whitney u-test was used to compare
on-parametric values. Both univariate and multivariate logistic
egression analyses were used to examine the association between
redictive variables and biopsy outcomes. Crude or adjusted odds
atios and 95% confidence intervals (CI) were calculated. Univari-
te logistic regression analysis indicated that age, total PSA, DRE,
SAD, history of smoking and alcohol consumption were the six
ignificant predictors for a positive prostate biopsy. A stepwise mul-
ivariate logistic regression analysis showed that the most significant
f the six risk factors for detecting prostate cancer were total PSA,
RE PSAD and history of alcohol consumption. Based on the final
odel, the estimated probability of a positive biopsy was calcu-
ated and a nomogram was accordingly developed as a clinical tool.
-values less than 0.05 were also considered significant.
esultsable 1 shows comparison of clinical prostate-related characteris-
ics and diagnostic parameters of all participants, PCa and without
Ca patients. Of 241 patients, PCa was found in 63 (26.1%) and 178
nostic parameters of all participants, PCa and without PCa patients.
Ca (n = 63) Without PCa (n = 178) P-value
1.8 ± 6.8 69.7 ± 8.8 0.094
 (3.2%) 21 (11.8%) 0.036
8 (28.6%) 64 (36.0%)
6 (57.1%) 68 (38.2%)
 (11.1%) 25 (14.0%)
9.6 (21.0–91.3) 12.9 (5.6–23.6) <0.0001
<0.0001
 (1.6%) 29 (16.3%)
 (6.3%) 52 (29.2%)
 (11.1%) 32 (18.0%)
9 (46.0%) 52 (29.2%)
2 (34.9%) 13 (7.3%)
<0.0001
4 (69.8%) 58 (32.58%)
9 (30.2%) 120 (67.41%)
.40 (0.18–0.77) 0.12 (0.007–0.33) <0.0001
<0.0001
0 (15.87%) 101 (56.7%)
3 (84.3%) 77 (43.3%)
6.9 (61.0–124.5) 80.65 (60.7–124.6) 0.600
0.385
 (9.5%) 18 (10.1%)
9 (30.2%) 70 (39.3%)
0 (60.3%) 90 (50.6%)
6.0–10.5) 9.0 (6.0–14.0) 0.262
03.8 (92.5–126.0) 106.2 (85.0–136.8) 0.569
2.3 ± 5.9 21.4 ± 5.7 0.121
tate Specific antigen, IQR = interquartile range, SD = standard deviation,
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Table  2  Univariate logistic regression analyses of diagnostic tools and identified risk factors for evaluating the risk of positive prostate biopsy
outcome.
Variables Patients Positive biopsy Odd ratio 95% CI P-value
Age (years) 0.095
Age groups (years)
50–69 105 20 (8.7%) Ref
≥70 136 43 (33.3%) 2.0 1.1–3.6 0.038
PSA(ng/ml) 0.002
PSA category (ng/ml)
≤20.0 125 12 (19.1%) Ref
>20.0 116 51 (780.1%) 7.6 3.8–15.9 <0.0001
DRE findings
Negative 102 44 (43.1%) Ref
Positive 139 19 (13.7%) 4.8 2.6–8.9 <0.0001
PSAD 0.001
PSAD category
<0.15 111 10 (9.0%) Ref
≥0.15 130 53 (40.8%) 6.9 3.3–14.5 <0.0001
History of smoking
No 174 52 (29.9%) Ref
Yes 67 11 (16.4%) 0.5 0.2–1.0 <0.036
History of alcohol consumption
No 168 55 (32.7%) Ref
0.3 0.1–0.6 0.001

































Table  3  Multiple logistic analyses of diagnostic tools and iden-
tified risk factors for evaluating the risk of positive prostate biopsy
outcome (Nomogram I).
Variables Odd ratio 95% CI P-value Beta
Age groups (years)
50–69 Ref
≥70 1.6 0.8–3.1 0.188 0.46
PSA category (ng/ml)
≤20.0 Ref
>20.0 3.3 1.3–7.6 0.014 1.18
DRE findings
Negative Ref
Positive 5.8 2.7–12.43 <0.0001 1.76
PSAD category
<0.15 Ref
≥0.15 3.1 1.1–8.20 0.023 1.12
History of smoking
No Ref
Yes 1.7 0.6–4.6 0.737 0.16
History of alcohol
No Ref
Yes 0.2 0.08–0.63 0.005 −1.5
Constant 0.0003 0.0002–0.049 <0.0001 −7.55
T
Yes 73 8 (11.0%) 
CI = confidence interval, DRE = digital rectal examination, PSA = prostate
73.9%) did not have cancer. Out of the total studied subjects, 30
f them (12.5%) had PSA <4 ng/ml, 23.2% had their PSA between
.1–10 ng/ml, 16.2% had PSA between 10.1–20 ng/ml, 33.6% had
SA between 20.1–50 ng/ml and 14.5% had PSA >50.0 ng/ml. The
ositive DREs detected among subjects were 57.7%. Higher pro-
ortion (53.9%) of all participants had PSAD >0.15 ng/ml/ml. With
egards to age, majority (57.1%) of participants with cancer were
ged of 70–79 years. Greater proportion (46.0%) of cancer subjects
ere in the PSA range of 20.1–50.0 ng/ml followed by >50.0 ng/ml
34.9%). Of the cancer subjects 69.8% had positive DRE at the initial
creening stage. Higher proportion of cancer subjects (84.3%) had
SAD ≥  0.15 ng/ml/ml. Total serum PSA and PSA Density (PSAD)
ere significantly higher (p < 0.0001) in subjects with PCa than sub-
ects without PCa. There was no significant difference in the mean
ge and prostate volume between subjects with and without prostate
ancer (p > 0.05). There was a significant difference in age groups,
RE findings, PSA categories and PSAD between subjects with and
ithout cancer (p < 0.0001).
able 2 shows the univariate analysis of diagnostic tools and
dentified risk factors for evaluating the risk of positive prostate
iopsy outcome. The results of the univariate logistic regres-
ion analysis showed that age, prostate specific antigen (PSA),
igital rectal examination (DRE), PSA Density (PSAD), history
f smoking and history of alcohol consumption in men with
nitial positive prostate biopsy were all significantly different
rom those in men with negative biopsy (p < 0.05). Participants
ho were above 70 years recorded increased odds ratios of 2.0
95% CI, 1.1–2.6). Moreover, increased PSA [OR = 7.6(3.8–15.9),
 < 0.0001], PSAD [OR = 6.9(3.3–14.5), p < 0.0001] and abnormal
RE findings [OR = 4.8(2.6-8.9), p < 0.0001] were statistically sig-






CI = confidence interval, DRE = digital rectal examination,
PSA = prostate specific antigen, PSAD = prostate Specific antigen
density.
able 3 shows the multiple logistic regression analysis of diag-
ostic tools and identified risk factors for evaluating the risk
f positive prostate biopsy outcome. The results of the mul-
iple logistic regression analyses showed that prostate specific
ntigen (PSA), DRE, PSAD and history of alcohol consump-
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Figure  1  Shows nomogram I for predicting the probability of prostate cancer on needle biopsy using age, PSA category, PSAD category, history
of smoking, history of alcohol consumption, and DRE findings. To determine the predicted probability of prostate cancer on initial biopsy, the
patient’s values are located on each axis. A vertical line is drawn to the ‘Score’ axis is drawn to determine how many points are attributed to each
 ‘Total  Scores’ is located on the total score axis to determine the individual
lity of Prostate Cancer’ line.
Table  4  Multiple logistic analyses of diagnostic tools factors for
evaluating the risk of positive prostate biopsy outcome (Nomogram
II).
Variable Odd ratio 95% CI P-value Beta
PSA category (ng/ml)
≤20.0 Ref
>20 3.0 1.1–7.8 0.027 1.04
DRE findings
Negative Ref
Positive 5.4 2.6–10.8 <0.0001 1.72
PSAD category
<0.15 Ref
≥0.15 3.8 1.4–10.9 0.010 0.94
Constant 0.01 0.001–0.08 <0.0001 −4.59
CI = confidence interval, DRE = digital rectal examination,
b
a
variable. After summation of the points for all variables, the sum on the
probability of prostate cancer on initial prostate biopsy on the ‘Probabi
tion in men with initial positive prostate biopsy were all
significantly different from those in men with negative biopsy
(p < 0.05). Moreover, increased PSA [OR = 3.3(1.3–7.6), p = 0.014],
PSAD [OR = 3.1(1.1–8.2), p = 0.023] and abnormal DRE findings
[OR = 5.8(2.7–12.4), p < 0.0001] were statistically significantly
associated with increased odds of developing prostate cancer respec-
tively. The Hosmer–Lemeshow good of fit test showed that the
model was well calibrated p equal to 0.325.
Table 4 shows the multiple logistic regression analysis of
diagnostic tools for evaluating the risk of positive prostate
biopsy outcome. In the multiple logistic regression analysis,
PSA, PSAD and DRE in men were found to be signifi-
cant independent predictors of initial positive prostate biopsy
(p < 0.05). Increased PSA [OR = 3.0(1.1–7.8), p = 0.027], PSAD
[OR = 3.8 (1.4–10.9), p = 0.010] and abnormal DRE findings
[OR = 5.4(2.6–10.8), p < 0.0001] were statistically significantly
associated with increased odds of developing prostate cancer respec-
tively. The Hosmer–Lemeshow good of fit test showed that the
model was well calibrated p equal to 0.283.
DiscussionConventionally, prostate biopsy is often performed with caution, yet
various invasive procedure-associated complications after prostate





PSA = prostate specific antigen, PSAD = prostate Specific antigen
density.
iopsy to detect PCa globally [16,17]. Recent studies have reported
n increase in the occurrence of infections after trans-rectal prostrate
iopsy [17,18]. It is therefore clinically imperative that, the decision
o perform a prostate biopsy is carefully made, so as to avoid the risk
f probable procedure-related complications. Although nomograms
ave been developed in some parts of the world, there is paucity of
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Figure  2  Shows nomogram II for predicting the probability of prostate cancer on needle biopsy using PSA category, PSAD category and DRE
findings. To determine the predicted probability of prostate cancer on initial biopsy, the patient’s values are located on each axis. A vertical line
to the ‘Score’ axis is drawn to determine how many points were attributable to each variable. After summation of the points for all variables, the













































nformation on the use on nomogram model to the clinical outcome
f a prostate biopsy in Ghana. This study is the first to develop
 predictive model that incorporates clinical and laboratory data
rom general practice and examine the accuracy of a nomogram for
he prediction of the prostate cancer risk in a Ghanaian population
Fig. 1).
eliable nomogram that can accurately predict and differentiate
he presence of aggressive prostate cancer from benign conditions
ould be useful to urologists and patients to make relevant clinical
ecisions [19]. In the current dataset for nomogram development,
e found that age, DRE PSA, PSAD, history of smoking, and his-
ory of alcohol consumption were significant independent predictors
p < 0.05) of prostate cancer and were used for the nomogram pre-
ictor variables. These findings are consistent with those in previous
eports from systematic review and the prevention trial and European
andomized study [20,21]. Furthermore, several factors such as age,
rostate specific antigen, free PSA, family history, race and abnor-
al DRE findings have been used as a predictor of prostate cancer
11,19,22]. However, after multivariate analysis it was found that,
ge and history of smoking were not independent predictors of pos-
tive initial prostate biopsy (p > 0.05) in this current study. Previous
tudies among Americans and Canadian men by Nam et al., [18] and





sing clinical parameters and identified risk factors. We developed
nd internally validated two (2) nomograms in this present study
hat predicted the probability of PCa in men referred for prostate
eedle biopsy. Using clinical parameters such as DRE, PSA and
SAD, the predicting AUC of the nomogram was 84.8%. It was
herefore observed that addition of the identified risk factors such
s age, history of smoking, and alcohol consumption improves the
UC to 87.7%. Thus the two nomograms developed in our present
tudy would appropriately predict 84.8% and 87.3% of patients with
Ca in a set of one hundred randomly paired patients in which only 1
ubject has cancer of the prostate on needle biopsy and the other does
ot. These observed values from the current study are higher com-
ared to those previously reported regressions-based nomograms for
atients with localized PCa [6,23–26]. The results from this study
avorably relates to the nature of the predictor variables used in the
mployed nomograms; namely age, DRE, PSA, history of smoking,
istory of alcohol consumption and PSAD. Indeed these predictors
n combination have been shown to be more informative and reliable
n the diagnosis of prostate cancer (Fig. 2).n the Ghanaian setting, there is a widespread use of the PSA, DRE
nd PSAD tests, thus Ghanaian men are more frequently referred
or biopsy under these conditions. However, in the present study,
e found that the accuracy of nomogram I and II for predicting
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Figure  3  Shows the area under the receiver-operating characteristic curve (AUC) for showing the accuracy of nomogram I, nomogram II, PSA




























(71.5–84.0) for PSAD and 75.8 (69.2–82.5) respectively with significan
a positive initial prostate biopsy was better than using PSA levels
alone (AUCs were 87.3%, 84.8 vs. 75.8%, respectively) (Fig. 3).
Similar trends were also shown between the PSAD, DRE and the
two nomograms respectively (AUC were 78.9%, 68.6% vs. 87.3%,
84.8%). While these results are similar with those reported from
previous studies from developed countries [19,27–29], this is the
first time such findings are observed in a Ghanaian setting, using
a Ghanaian cohort. Previous studies have not included PSAD in
most prostate nomogram model, although PSAD has been shown
in several studies to have a better accuracy than PSA and DRE
[30–32]. A higher median PSAD value in our study was observed
because PSAD testing is still not routinely used for early detection
of prostate cancer in Ghana. Thus, the majority of prostate cancers
are diagnosed at a later disease stage. PSAD, which was included
in our predictive model, may also be a key factor in improving the
accuracy of the nomogram.
Regression-based model needs to be calibrated and validated in
patients with similar disease characteristics before usage since a gen-
eralized application of a model may various patient characteristics.
In this study, the two nomograms developed were well calibrated
by the Hosmer–Lemeshow good of fit test (p = 0.325 and = 0.283)
and validated internally with 500 bootstrapped re-samples. Most
of the predictors used in the development of the two nomograms
were significant in the bootstrapped output. These internal valid-
ity estimates demonstrated less pronounced differences between
development and internal validation samples than were observed
for the prostate biopsy nomograms. These findings are consistent
with to previous studies on internally validated regression-based
nomograms by Tang et al., [27], Garzotto et al., [23] and Thompson
et al., [26] in the Chinese and Western population though nomo-
gram in these studies demonstrated minimal decrease in predictive
accuracy relative to our nomograms. However, Hernandez et al.,
[25], Suzuki et al., [6] and Park et al., [24] failed to validate their





 single, tertiary hospital, which may lead to partial results and our
omograms have not been validated externally. Whether it can be
niversally applied to Ghanaian populations must be confirmed, and
urther larger, prospective and randomized studies are necessary.
onclusion
omograms offer a better and accurate assessment for predicting a
ositive outcome of prostate biopsies than the use of traditional tools
f PSA, DRE and PSAD in predicting the prostate biopsy outcome
uch as presence of prostate cancer and benign prostatic hyperplasia.
urthermore, this study reflected a hospital-based screening popu-
ation and validated internally for its accuracy. The study provides
 base line for further studies probably using, a multi-institutional
tudy with larger population is strongly recommended.
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